- Home
- IGMS vs CODA Comparison
IGMS vs CODA Comparison
Compare IGMS & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- CODA
- Stock Information
- Founded
- IGMS 1993
- CODA 1994
- Country
- IGMS United States
- CODA United States
- Employees
- IGMS N/A
- CODA N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- CODA Industrial Machinery/Components
- Sector
- IGMS Health Care
- CODA Industrials
- Exchange
- IGMS Nasdaq
- CODA Nasdaq
- Market Cap
- IGMS 82.1M
- CODA 92.5M
- IPO Year
- IGMS 2019
- CODA N/A
- Fundamental
- Price
- IGMS $1.13
- CODA $6.77
- Analyst Decision
- IGMS Hold
- CODA Strong Buy
- Analyst Count
- IGMS 8
- CODA 1
- Target Price
- IGMS $6.14
- CODA $11.00
- AVG Volume (30 Days)
- IGMS 155.8K
- CODA 46.1K
- Earning Date
- IGMS 05-20-2025
- CODA 06-11-2025
- Dividend Yield
- IGMS N/A
- CODA N/A
- EPS Growth
- IGMS N/A
- CODA 61.24
- EPS
- IGMS N/A
- CODA 0.34
- Revenue
- IGMS $2,679,000.00
- CODA $21,064,685.00
- Revenue This Year
- IGMS $121.76
- CODA $11.64
- Revenue Next Year
- IGMS $46.83
- CODA $14.53
- P/E Ratio
- IGMS N/A
- CODA $19.42
- Revenue Growth
- IGMS 25.77
- CODA 15.63
- 52 Week Low
- IGMS $0.92
- CODA $5.76
- 52 Week High
- IGMS $22.50
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- IGMS 39.53
- CODA 54.68
- Support Level
- IGMS $1.11
- CODA $6.41
- Resistance Level
- IGMS $1.40
- CODA $7.09
- Average True Range (ATR)
- IGMS 0.11
- CODA 0.40
- MACD
- IGMS -0.01
- CODA 0.04
- Stochastic Oscillator
- IGMS 5.56
- CODA 65.03
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.